National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment HTG781 17 September 2026 17 September 2026 ...
The National Institute for Health and Care Excellence

MHRA and NICE aligned pathway: how it's working in practice

Although the aligned pathway is central to our work, the benefits of improved collaboration between MHRA and NICE go beyond it. A recent example is aficamten, a new daily pill for people with ...
National Institute for Health and Care Excellence

Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS

The benefits of the new Alzheimer’s drug lecanemab are too small to justify the costs, NICE said in draft guidance published today. Lecanemab (also called Leqembi and made by Eisai) is for slowing ...
National Institute for Health and Care Excellence

Weekly insulin jab could cut injections from 365 a year to just 52

Hundreds of thousands of people with type 2 diabetes could swap daily insulin injections for a once-a-week jab, following a NICE recommendation today (Thursday, 20 August). The switch could cut the ...
National Institute for Health and Care Excellence

BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups

This guidance has been updated and replaced by obesity: identification, assessment and management ...
National Institute for Health and Care Excellence

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

This guidance has been updated and replaced by NICE technology appraisal guidance TA798 ...
National Institute for Health and Care Excellence

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer

This guidance has been updated and replaced by NICE technology appraisal guidance 946 ...
National Institute for Health and Care Excellence

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes

Access to hybrid closed loop systems will be through a 5-year phased roll out in line with NHS England's implementation plan. For enquiries about cost-effective pricing contact ...
National Institute for Health and Care Excellence

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...
National Institute for Health and Care Excellence

Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment

We have moved Health technology evaluation 7 to become HealthTech guidance 674. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...